<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel>
    <title>Journal of Clinical Investigation -- New Articles</title>
    <link>http://www.jci.org/just-published</link>
    <description>
      <![CDATA[Journal of Clinical Investigation RSS feed -- New Articles Published]]>
    </description>
    <language>en-us</language>
    <copyright>2009 The American Society for Clinical Investigation</copyright>
    <image>
      <title>Journal of Clinical Investigation</title>
      <url>http://www.jci.org/icons/banner/rss_title.gif</url>
      <link>http://content.jci.org</link>
    </image>
    <item>
      <title>
        <![CDATA[Regulator of G protein signaling 2 mediates cardiac compensation to
               pressure overload and antihypertrophic effects of PDE5 inhibition in
            mice]]>
      </title>
      <author>Eiki Takimoto, Norimichi Koitabashi, Steven Hsu, Elizabeth A. Ketner, Manling Zhang, Takahiro Nagayama, Djahida Bedja, Kathleen L. Gabrielson, Robert Blanton, David P. Siderovski, Michael E. Mendelsohn, David A. Kass</author>
      <dc:creator>
        <![CDATA[Eiki Takimoto, Norimichi Koitabashi, Steven Hsu, Elizabeth A. Ketner, Manling Zhang, Takahiro Nagayama, Djahida Bedja, Kathleen L. Gabrielson, Robert Blanton, David P. Siderovski, Michael E. Mendelsohn, David A. Kass]]>
      </dc:creator>
      <link>http://www.jci.org/articles/view/35620</link>
      <description>
        <![CDATA[The heart initially compensates for hypertension-mediated pressure overload by
               enhancing its contractile force and developing hypertrophy without dilation.
               G<sub>q</sub> protein&#x02013;coupled receptor pathways become activated and can
               depress function, leading to cardiac failure. Initial adaptation mechanisms to reduce
               cardiac damage during such stimulation remain largely unknown. Here we have shown
               that this initial adaptation requires regulator of G protein signaling 2 (RGS2). Mice
               lacking RGS2 had a normal basal cardiac phenotype, yet responded rapidly to pressure
               overload, with increased myocardial G<sub>q</sub> signaling, marked cardiac
               hypertrophy and failure, and early mortality. Swimming exercise, which is not
               accompanied by G<sub>q</sub> activation, induced a normal cardiac response, while
                  <i>Rgs2</i> deletion in G<sub>&#x003b1;q</sub>-overexpressing hearts
               exacerbated hypertrophy and dilation. In vascular smooth muscle, RGS2 is activated by
               cGMP-dependent protein kinase (PKG), suppressing G<sub>q</sub>-stimulated vascular
               contraction. In normal mice, but not
                  <i>Rgs2<sup>&#x02013;/&#x02013;</sup></i> mice, PKG activation
               by the chronic inhibition of cGMP-selective phosphodiesterase 5 (PDE5) suppressed
               maladaptive cardiac hypertrophy, inhibiting G<sub>q</sub>-coupled stimuli.
               Importantly, PKG was similarly activated by PDE5 inhibition in myocardium from both
               genotypes, but PKG plasma membrane translocation was more transient in
                     <i>Rgs2<sup>&#x02013;/&#x02013;</sup></i> myocytes than in
               controls and was unaffected by PDE5 inhibition. Thus, RGS2 is required for early
               myocardial compensation to pressure overload and mediates the initial
               antihypertrophic and cardioprotective effects of PDE5 inhibitors. ]]>
      </description>
      <identifer>info:doi/10.1172/JCI35620</identifer>
      <publisher>American Society for Clinical Investigation</publisher>
    </item>
    <item>
      <title>
        <![CDATA[COX2 in CNS neural cells mediates mechanical inflammatory pain hypersensitivity in mice]]>
      </title>
      <author>Daniel Vardeh, Dairong Wang, Michael Costigan, Michael Lazarus, Clifford B. Saper, Clifford J. Woolf, Garret A. FitzGerald, Tarek A. Samad</author>
      <dc:creator>
        <![CDATA[Daniel Vardeh, Dairong Wang, Michael Costigan, Michael Lazarus, Clifford B. Saper, Clifford J. Woolf, Garret A. FitzGerald, Tarek A. Samad]]>
      </dc:creator>
      <link>http://www.jci.org/articles/view/37098</link>
      <description>
        <![CDATA[A cardinal feature of peripheral inflammation is pain. The most common way of managing inflammatory pain is to use nonsteroidal antiinflammatory agents (NSAIDs) that reduce prostanoid production, for example, selective inhibitors of COX2. Prostaglandins produced after induction of COX2 in immune cells in inflamed tissue contribute both to the inflammation itself and to pain hypersensitivity, acting on peripheral terminals of nociceptors. COX2 is also induced after peripheral inflammation in neurons in the CNS, where it aids in developing a central component of inflammatory pain hypersensitivity by increasing neuronal excitation and reducing inhibition. We engineered mice with conditional deletion of <i>Cox2</i> in neurons and glial cells to determine the relative contribution of peripheral and central COX2 to inflammatory pain hypersensitivity. In these mice, basal nociceptive pain was unchanged, as was the extent of peripheral inflammation, inflammatory thermal pain hypersensitivity, and fever induced by lipopolysaccharide. By contrast, peripheral inflammation&#x02013;induced COX2 expression in the spinal cord was reduced, and mechanical hypersensitivity after both peripheral soft tissue and periarticular inflammation was abolished. Mechanical pain is a major symptom of most inflammatory conditions, such as postoperative pain and arthritis, and induction of COX2 in neural cells in the CNS seems to contribute to this.
            ]]>
      </description>
      <identifer>info:doi/10.1172/JCI37098</identifer>
      <publisher>American Society for Clinical Investigation</publisher>
    </item>
  </channel>
</rss>
